Glooko – Weekly Recap

Glooko featured prominently this week as the digital diabetes care company secured multiple forms of external validation and advanced its integrated data strategy. The company’s connected-care software portfolio won the “Best Overall MedTech Software” award at the 10th annual MedTech Breakthrough Awards, underscoring the perceived quality and innovation of its diabetes and glycemic management tools.

This recognition covers Glooko’s software across inpatient and outpatient settings and may strengthen its competitive positioning with hospitals, health systems, and providers. Increased third-party validation could support customer acquisition and partnership discussions as health organizations seek robust digital tools for chronic disease management.

Glooko also aligned its EndoTool Analytics offering with new Centers for Medicare & Medicaid Services rules that elevate severe hypoglycemia and hyperglycemia to enterprise-level quality metrics. The company is positioning its analytics to help hospitals move beyond simple event reporting toward deeper insights into event locations, workflow drivers, and areas for intervention.

By emphasizing earlier intervention and glycemic safety, Glooko is targeting operational and clinical pain points that affect quality scores and risk management. If hospitals respond to CMS expectations by prioritizing data-driven glycemic management, demand for enterprise analytics solutions like EndoTool could grow, supporting future revenue opportunities.

Leadership credibility was another theme, as Chief Medical and Strategy Officer Mark Clements was named to Becker’s Healthcare 2026 “Great Leaders in Healthcare” list. The recognition highlights his role in advancing evidence-based, clinically grounded diabetes care and integrating digital health with research and practice.

This leadership visibility may enhance Glooko’s standing with providers, payers, and strategic partners and supports a narrative of clinically validated product development. Such positioning can be important for reimbursement, regulatory acceptance, and differentiation from more consumer-focused health apps.

On the commercial and clinical engagement front, Glooko showcased its solutions at the 38th Annual Diabetes Conference in North Carolina. The company highlighted inpatient and outpatient connected-care offerings designed to improve outcomes and streamline clinician workflows.

Glooko’s broader strategy centers on building an integrated diabetes data ecosystem that spans hospital and ambulatory settings and emphasizes interoperability and workflow automation. Overall, the week underscored growing external validation, regulatory alignment, and ecosystem engagement, reinforcing Glooko’s long-term positioning in digital diabetes management.